<DOC>
	<DOCNO>NCT02988674</DOCNO>
	<brief_summary>The objective study access retention rate , persistence adherence population spondylarthritis ( SpA ) ( ankylose spondylitis ( AS ) psoriatic arthritis ( PsA ) ) participant treat adalimumab routine clinical setting Russian Federation .</brief_summary>
	<brief_title>A Study Assess Retention Rate , Persistence Adherence Population Spondylarthritis ( Ankylosing Spondylitis Psoriatic Arthritis ) Patients Treated With Adalimumab Routine Clinical Settings Russian Federation</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Confirmed diagnosis AS PsA . Planned prescription prescribe 1 month enrolment therapy adalimumab . Treatment prescribe accord local product label prescription guideline . At moment start treatment adalimumab moderate/severe AS PsA ( BASDAI &gt; 4 AS ; DAS28 &gt; 3,2 PsA ) . Negative result tuberculosis ( TB ) screen test TB specialist permission start biologic therapy . Authorization ( Consent ) Use/Disclosure Data sign participant . Has contraindication treatment adalimumab ( please see late version locally approve label ) . Participants unable walk perform basic selfcare activity either due SpA comorbid condition . Any biologic drug take 3 month enrolment study . Previous participation program .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Ankylosing spondylitis</keyword>
	<keyword>HumiraÂ®</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Spondylarthritis</keyword>
	<keyword>Psoriatic arthritis</keyword>
</DOC>